StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
PULM stock opened at $2.12 on Wednesday. The stock has a fifty day moving average of $2.09 and a 200-day moving average of $2.01. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The company has a market capitalization of $7.75 million, a price-to-earnings ratio of -0.88 and a beta of 1.00.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. The business had revenue of $1.55 million during the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Insider Selling Explained: Can it Inform Your Investing Choices?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
